4.7 Article

Effects of prenatal and postnatal maternal multiple micronutrient supplementation on child growth and morbidity in Tanzania: a double-blind, randomized-controlled trial

Journal

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Volume 51, Issue 6, Pages 1761-1774

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ije/dyab117

Keywords

Pregnancy; women; micronutrients; supplementation; anaemia; vitamin; lactation; postpartum; Tanzania

Funding

  1. Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health [NICHD R01 37701]

Ask authors/readers for more resources

While prenatal MMS showed modest improvements in weight and length z-scores in the first 6 months of life, it did not have lasting effects. Prenatal or postnatal MMS did not show significant benefits for other child outcomes.
Background Maternal micronutrient status is critical for child growth and nutrition. It is unclear whether maternal multiple micronutrient supplementation (MMS) during pregnancy and lactation improves child growth and prevents child morbidity. Methods This study aimed to determine the effects of prenatal and postnatal maternal MMS on child growth and morbidity. In this double-blind, randomized-controlled trial, 8428 HIV-negative pregnant women were enrolled from Dar es Salaam, Tanzania, between 2001 and 2004. From pregnancy (12-27 weeks of gestation) through to 6 weeks postpartum, participants were randomized to receive daily oral MMS or placebo. All women received daily iron and folic acid during pregnancy. From 6 weeks postpartum through to 18 months postpartum, 3100 women were re-randomized to MMS or placebo. Child-growth measures, haemoglobin concentrations and infectious morbidities were assessed longitudinally from birth to <= 18 months. Results Prenatal MMS led to modest increases in weight-for-age z-scores (mean difference: 0.050; 95% confidence interval: 0.002, 0.099; p = 0.04) and length-for-age z-score (mean difference: 0.062; 95% confidence interval: 0.013, 0.111; p = 0.01) during the first 6 months of life but not thereafter. Prenatal or postnatal MMS did not have benefits for other child outcomes. Conclusions Whereas maternal MMS is a proven strategy to prevent adverse birth outcomes, other approaches may also need to be considered to curb the high burdens of child morbidity and growth faltering.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available